Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 4 studies | 20% ± 2% | |
oligodendrocyte | 3 studies | 20% ± 2% |
Insufficient scRNA-seq data for expression of PTDSS2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1825.80 | 1445 / 1445 | 100% | 11.88 | 183 / 183 |
ovary | 100% | 3053.48 | 180 / 180 | 100% | 17.37 | 430 / 430 |
pancreas | 100% | 1361.26 | 328 / 328 | 100% | 13.83 | 178 / 178 |
brain | 100% | 2594.07 | 2641 / 2642 | 100% | 31.53 | 705 / 705 |
thymus | 100% | 2602.55 | 653 / 653 | 100% | 21.16 | 604 / 605 |
uterus | 100% | 2609.43 | 170 / 170 | 100% | 16.57 | 458 / 459 |
skin | 100% | 1695.53 | 1808 / 1809 | 100% | 27.38 | 471 / 472 |
kidney | 100% | 2515.54 | 89 / 89 | 100% | 20.59 | 897 / 901 |
prostate | 100% | 2562.40 | 245 / 245 | 99% | 23.38 | 499 / 502 |
stomach | 100% | 1651.45 | 359 / 359 | 99% | 16.06 | 283 / 286 |
intestine | 100% | 1929.96 | 966 / 966 | 99% | 17.59 | 521 / 527 |
breast | 100% | 1802.43 | 459 / 459 | 99% | 16.83 | 1104 / 1118 |
adrenal gland | 100% | 2708.14 | 258 / 258 | 99% | 15.78 | 227 / 230 |
bladder | 100% | 2058.29 | 21 / 21 | 99% | 15.99 | 497 / 504 |
lung | 100% | 1891.07 | 577 / 578 | 98% | 13.58 | 1137 / 1155 |
liver | 100% | 980.72 | 226 / 226 | 98% | 12.36 | 398 / 406 |
adipose | 100% | 1818.42 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 53.37 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 15.58 | 29 / 29 |
spleen | 100% | 1782.43 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 12.01 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.99 | 1 / 1 |
muscle | 100% | 1362.69 | 802 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1671.90 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 2078.89 | 859 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 80% | 615.80 | 739 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006659 | Biological process | phosphatidylserine biosynthetic process |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0016740 | Molecular function | transferase activity |
GO_0106245 | Molecular function | L-serine-phosphatidylethanolamine phosphatidyltransferase activity |
GO_0003882 | Molecular function | CDP-diacylglycerol-serine O-phosphatidyltransferase activity |
Gene name | PTDSS2 |
Protein name | Phosphatidylserine synthase 2 Phosphatidylserine synthase (EC 2.7.8.29) (Serine-exchange enzyme) Phosphatidylserine synthase 2 (PSS-2) (PtdSer synthase 2) (EC 2.7.8.29) (Serine-exchange enzyme II) |
Synonyms | PSS2 |
Description | FUNCTION: Catalyzes a base-exchange reaction in which the polar head group of phosphatidylethanolamine (PE) or phosphatidylcholine (PC) is replaced by L-serine . Catalyzes the conversion of phosphatatidylethanolamine and does not act on phosphatidylcholine . Can utilize both phosphatidylethanolamine (PE) plasmalogen and diacyl PE as substrate and the latter is six times better utilized, indicating the importance of an ester linkage at the sn-1 position (By similarity). Although it shows no sn-1 fatty acyl preference, exhibits significant preference towards docosahexaenoic acid (22:6n-3) compared with 18:1 or 20:4 at the sn-2 position (By similarity). . FUNCTION: Catalyzes a base-exchange reaction in which the polar head group of phosphatidylethanolamine (PE) is replaced by L-serine. . |
Accessions | ENST00000527479.5 A0A0J9YWQ2 ENST00000531520.5 Q9BVG9 E9PS47 E9PLE4 ENST00000308020.6 ENST00000633628.1 |